Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $10,800 | 7 | 69.3% |
| Unspecified | $4,718 | 3 | 30.3% |
| Food and Beverage | $61.03 | 3 | 0.4% |
| Education | $0.83 | 1 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ALBIREO PHARMA, INC. | $14,600 | 9 | $0 (2024) |
| F. Hoffmann-La Roche AG | $918.31 | 1 | $0 (2021) |
| Retrophin, Inc. | $44.93 | 3 | $0 (2019) |
| Alexion Pharmaceuticals, Inc. | $16.93 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,800 | 2 | ALBIREO PHARMA, INC. ($3,800) |
| 2023 | $3,200 | 3 | ALBIREO PHARMA, INC. ($3,200) |
| 2022 | $7,600 | 4 | ALBIREO PHARMA, INC. ($7,600) |
| 2021 | $918.31 | 1 | F. Hoffmann-La Roche AG ($918.31) |
| 2019 | $38.82 | 3 | Retrophin, Inc. ($21.89) |
| 2018 | $23.04 | 1 | Retrophin, Inc. ($23.04) |
All Payment Transactions
14 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/05/2024 | ALBIREO PHARMA, INC. | Bylvay (Drug) | — | Cash or cash equivalent | $2,000.00 | Research |
| Study: An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT) • Category: Gastroenterology | ||||||
| 05/09/2024 | ALBIREO PHARMA, INC. | Bylvay (Drug) | — | Cash or cash equivalent | $1,800.00 | Research |
| Study: An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT) • Category: Gastroenterology | ||||||
| 09/15/2023 | ALBIREO PHARMA, INC. | Bylvay (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: Gastroenterology | ||||||
| 08/17/2023 | ALBIREO PHARMA, INC. | Bylvay (Drug) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: Gastroenterology | ||||||
| 08/17/2023 | ALBIREO PHARMA, INC. | Bylvay (Drug) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: Gastroenterology | ||||||
| 11/23/2022 | ALBIREO PHARMA, INC. | Bylvay (Drug) | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| Category: Gastroenterology | ||||||
| 10/27/2022 | ALBIREO PHARMA, INC. | Bylvay (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: Gastroenterology | ||||||
| 06/09/2022 | ALBIREO PHARMA, INC. | Bylvay (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: Gastroenterology | ||||||
| 03/24/2022 | ALBIREO PHARMA, INC. | Bylvay (Drug) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: Gastroenterology | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | Pegasys (Biological) | — | In-kind items and services | $918.31 | Research |
| Study: PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG POSITIVE CHRONIC HEPATITIS B IN THE IMMUNE TOLERANT PHASE • Category: Virology & Specialty Care | ||||||
| 10/29/2019 | Retrophin, Inc. | (820) Cholbam (Drug) | Food and Beverage | In-kind items and services | $21.06 | General |
| Category: Hepatology | ||||||
| 07/29/2019 | Alexion Pharmaceuticals, Inc. | Kanuma (Drug) | Food and Beverage | In-kind items and services | $16.93 | General |
| Category: Immunology | ||||||
| 02/20/2019 | Retrophin, Inc. | (820) Cholbam (Drug) | Education | In-kind items and services | $0.83 | General |
| Category: Hepatology | ||||||
| 11/26/2018 | Retrophin, Inc. | (820) Cholbam (Drug) | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: Hepatology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT) | ALBIREO PHARMA, INC. | $3,800 | 2 |
| PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG POSITIVE CHRONIC HEPATITIS B IN THE IMMUNE TOLERANT PHASE | F. Hoffmann-La Roche AG | $918.31 | 1 |
About Dr. James Daniel, MD
Dr. James Daniel, MD is a Pediatric Gastroenterology healthcare provider based in Kansas City, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/22/2005. The National Provider Identifier (NPI) number assigned to this provider is 1659377919.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Daniel, MD has received a total of $15,580 in payments from pharmaceutical and medical device companies, with $3,800 received in 2024. These payments were reported across 14 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($10,800).
Practice Information
- Specialty Pediatric Gastroenterology
- Location Kansas City, MO
- Active Since 06/22/2005
- Last Updated 05/27/2011
- Taxonomy Code 2080P0206X
- Entity Type Individual
- NPI Number 1659377919
Products in Payments
- Bylvay (Drug) $14,600
- Pegasys (Biological) $918.31
- (820) Cholbam (Drug) $44.93
- Kanuma (Drug) $16.93
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Gastroenterology Doctors in Kansas City
Joel Lim, Md, MD
Pediatric Gastroenterology — Payments: $6,408
Ding-You Li, Md, MD
Pediatric Gastroenterology — Payments: $5,646
Rachel Chevalier, Md, MD
Pediatric Gastroenterology — Payments: $4,235
Thomas Attard, Md, MD
Pediatric Gastroenterology — Payments: $3,000
Julie Bass, Do, DO
Pediatric Gastroenterology — Payments: $2,796
Valentina Shakhnovich, M.d, M.D
Pediatric Gastroenterology — Payments: $1,070